Saudi Health Minister Fahad Abdulrahman Aljalajil addresses the Ministerial Conference on Antimicrobial Resistance (AMR) in Jeddah.

Government leaders from the health, environment and agriculture sectors in 57 countries adopted a 14-point plan to tackle antimicrobial resistance (AMR) at a meeting in Saudi Arabia that ended over the weekend.

One of the undertakings of the Jeddah Commitment is support for the establishment of an independent panel to collect evidence about AMR. 

The United Nations (UN) High-Level Meeting on AMR had already committed to such a panel in September and gave the Quadripartite (Quad) organisations –  the World Health Organization (WHO), Food and Agricultural Organization (FAO), UN Evironment Programme (UNEP) and World Organization for Animal Health (WOAH) – the authority to set up the panel.

The ministerial conference resolved to support the Quad in a “timely, open and transparent process” to set up  “an Independent Panel for Evidence on Action Against AMR”.

However further details, including which UN agency should host the panel and its terms of reference, have not yet been resolved.

The UK is believed to favour UNEP hosting the panel while other countries believe that the WHO is better equipped to do so as the global health body houses the Quad.

The declaration also call for the creation of a new “biotech bridge” to boost research, development and innovation to find solutions to AMR.

AMR happens when bacteria, viruses, fungi, and parasites develop resistance to medicines designed to kill them. This makes infections harder and more costly to treat. Drug-resistant pathogens can also spread between people, animals, and the environment. 

It is driven in large part by the misuse and overuse of antimicrobials, particularly in agriculture. AMR already causes an estimated 1.27 million deaths per year.

Saudi Arabia launches regional hubs

Meanwhile, Saudi Arabia will launch a regional antibiotic access and logistics hub and an AMR One Health learning hub, the country’s health minister, Fahd bin Abdulrahman Al-Jalajel, told conference delegates.

The access and logistics hub will initially operate as a pilot in the WHO’s Eastern Mediterranean Region (EMRO). Its purpose is to foster the sustainable procurement of antibiotics and diagnostics and improve end-to-end access to these. 

A conference participant told Health Policy Watch that the hub would stockpile antibiotics and establish distribution networks to ensure that they reach areas in need, particularly conflict zones. EMRO members include Palestine, Lebanon and Sudan. 

The One Health AMR Learning Hub will focus on sharing best practices and developing capabilities on how to implement national AMR action plans on AMR with specific national targets.

‘Misunderstanding’ of animal welfare 

Wendla-Antonia Beyer, policy officer at the farm animal welfare and public health organisation, Four Paws, said that while the Jeddah Commitment “shows there is momentum behind tackling AMR” it also shows that there is “insufficient understanding of how animal welfare impacts antibiotics use in farming”. 

Beyer said that “73% of our antibiotics are used in agriculture, often for growth-promotion or for diseases that could be prevented if farms had good animal welfare. 

“Farms where piglets spend more time with their mothers use less antibiotics. Farms with slower-growing chicken breeds use less antibiotics. The solutions are there, proven and viable — they only need to make it into policy and practice. With the Political Declaration and the Jeddah Commitment behind us, governments and global governance structures now need to make animal welfare an integral part of the One Health response to AMR.”

Katherine Urbáez, who heads the Health Diplomacy Alliance (HDA), said her organisation would “continue to advocate to ensure the continued political and financial commitment and to tackle AMR”.

“This includes the setting up of the panel with the scope and governance that allows the identification of the data and to advance the commitments in the HLM Policital Declaration”.

HDA is based in Geneva and works with multi-stakeholders to advance health with diplomacy.

This week is World AMR Awareness Week, which has its theme as “Educate. Advocate. Act now.”

Image Credits: Health Ministry of Saudi Arabia.

INB co-chair Anne-Claire Amprou and the WHO’s Mike Ryan at the close of INB12.

The latest draft of the World Health Organization’s (WHO) pandemic agreement is awash with green highlights – an indication that countries have reached consensus on much of the text.

But the Intergovernmental Negotiating Body (INB) announced on Monday that it would not be possible to reach an agreement by December – and countries would push for the adoption of an agreement by the World Health Assembly (WHA) next May.

During the past two weeks of the 12th meeting of the INB, progress has been made on research and development(Article 9), local production(Article 10) and regulatory systems strengthening (Article 14).

Sticking points

But Article 4 on prevention, which details countries’ pandemic prevention and surveillance obligations, is mostly highlighted in yellow. This means that countries have broad agreement on the text but much of the detail is not agreed.

Many of the proposals are common sense – such as building the capacity to detect pathogens at the community level, routine immunisation, and prevention of zoonotic spillover. 

But these measures are a tall order for some low-income countries, which is partly where the resistance is coming from. Under-resourced countries are unsure of how much prevention will cost them and whether they will get help to implement the provisions. Wealthier countries want assurances that their poorer neighbours can contain outbreaks.

The rapid spread of mpox in central Africa is an example. Several affected countries have been unable to confirm cases as they lack basic diagnostic laboratories and trained staff. 

Negotiators are considering a separate annex on prevention, much as the details of a  Pathogen Access and Benefit Sharing (PABS) system may be accommodated in a separate annex. 

Sticking points also remain on technology transfer (Article 11), the PABS system (Article 12), the global supply chain and logistic (GSCL) system (Article 13) and sustainable financing (Article 20).

However, the most tangible offering of the agreement is back on the table although not yet agreed: that 20% of vaccines, therapeutics and diagnostics produced to combat that pathogen during a pandemic will be allocated to the WHO for distribution with 10% given free and the remaining amount on yet-to-be determined terms.

Earlier, there were reports that some members of the European Union wanted this requirement to be cut down to 10% and 5% respectively.

‘Crucial and delicate’

Tanzanian Ambassador Dr Abdallah Saleh Possi.

Tanzanian Ambassador Dr Abdallah Saleh Possi, speaking for the 47 African member states and Egypt, expressed Africa’s disappointment that there was not sufficient consensus to call a special World Health Assembly next month.

“Although we had such slow progress in this 12th session that did not realize the convening of a special session in December as anticipated, we all agree that the remaining issues are not many, but crucial and delicate, requiring decision-making and flexibility,” said Possi at the close of the two-week negotiations on Friday.

“Significantly, the meeting has generated the commitment to finalize them. We thank all the delegations that organize informal meetings on some sticky areas. We support having informal sessions during inter-sessional period with a view to achieving consensus on key areas. The Africa group plus Egypt is happy to be amongst the groups seeking to find consensus on the remaining issues.”

The Philippines on behalf of the Equity Group, expressed appreciation for both the “substantive progress” particularly on articles, 9,10 and 14, and “the cordiality displayed by delegations that helped bring about this progress”. 

However, warned the Philippines’ delegate, “much work needs to be done to achieve consensus on key articles that operationalize equity such as articles, 11,12, 13, 13 (bis)  and 20.”

Unlike the Africa Group, which wanted a December resolution, the Equity Group has always advocated for more time to deliberate on the agreement.

The negotiators reconvene for a short INB session from 2-6 December, where they will decide on the programme of negotiations for 2025.

Robert F. Kennedy Jr, scion of America’s most prominent political family, is set to become the nation’s top health official under Trump.

Donald Trump has named Robert F Kennedy Jr as his choice for US health secretary, putting the controversial anti-vaccine activist and environmental lawyer in line to control some of the world’s most influential health agencies.

Kennedy shot to political prominence during the COVID-19 pandemic when his organisation, Children’s Health Defense, became a leading global voice questioning vaccine safety and efficacy. His appointment, which requires Senate confirmation, comes after Kennedy dropped his independent presidential bid to back Trump.

“He’s going to help make America healthy again,” Trump said in a speech at Mar-a-Lago following his election victory. “He wants to do some things, and we’re going to let him get to it.”

Trump described the role atop HHS as “the most important role of any administration”, adding that Kennedy “will play a big role in helping ensure that everybody will be protected from harmful chemicals, pollutants, pesticides, pharmaceutical products, and food additives that have contributed to the overwhelming Health Crisis in this Country”.

If confirmed, Kennedy would oversee a sprawling $1.8 trillion department with 10 health agencies and three human services agencies. 

His leadership of HHS would include the administration of Medicare, Medicaid and the Affordable Care Act while setting priorities for America’s three most powerful health agencies: the Centers for Disease Control and Prevention (CDC), which tracks disease outbreaks and sets public health guidance; the Food and Drug Administration (FDA), which approves medicines and medical devices; and the National Institutes of Health (NIH), the world’s largest public funder of medical research.

Kennedy, an environmental lawyer with no health experience, called his appointment “a generational opportunity” to realign US health policy and “put an end to the chronic disease epidemic” in a post accepting the nomination on X. He said Trump has instructed him to “reorganize” the U.S. constellation of federal health agencies.

“I look forward to working with the more than 80,000 employees at HHS to free the agencies from the smothering cloud of corporate capture so they can pursue their mission to make Americans once again the healthiest people on Earth,” Kennedy said. 

Global health fallout

Beyond domestic agencies, the Trump administration is also expected to reshape America’s role in global health.

In his last term, Trump withdrew funding from the World Health Organization over its COVID-19 response and slashed funding to UN agencies, leaving a multi-billion dollar gap in the UN health agency’s budget. With Kennedy – who has questioned global health orthodoxies – by his side, experts expect this isolationist stance to deepen.

This could affect millions who rely on HIV/AIDS funding through PEPFAR, a $7 billion US program providing HIV treatment in over 50 countries, the CDC’s network of 65 international offices, and State Department health diplomacy efforts.

WHO officials told Health Policy Watch last month they face “a huge fear factor” over potential US funding withdrawal, warning the agency would enter “a dramatically bad crisis” without American support.

The Biden administration’s global health security team referred Health Policy Watch to the Trump transition team when asked for comment.

Robert Kennedy Junior’s banner photo on X, formerly Twitter, where he boasts over 4.5 million followers.

Beyond the mainstream

Kennedy’s stated priorities for America’s health system veer from broadly supported reforms to debunked anti-scientific claims that have alarmed health experts.

In recent weeks, he has called for removing fluoride from US drinking water – which he claims causes brain disease – reviewing vaccine safety data with an eye to withdrawing some from the market, eliminating “entire departments” at the FDA, and immediately dismissing 600 NIH employees.

His controversial positions include claims repeatedly rejected by scientists: that vaccines cause autism in children, that AIDS is not caused by HIV, that antidepressants are responsible for mass school shootings, and that atrazine, a widely used herbicide, triggers gender dysphoria and has led to increases in young people identifying as transgender.

Kennedy’s unconventional streak isn’t limited to medicine. In the run-up to November’s election, Kennedy said doctors found a worm had eaten part of his brain, video footage revealed him to be the key to a decade-old New York City mystery of a dead bear in Central Park – he dumped it there on his way to the airport – and came under investigation for decapitating a whale.

Lawrence Gostin, a global health expert at Georgetown University, called the Kennedy pick “the darkest day for public health and science in my lifetime.”

“Trump’s pick of RFK Jr as HHS Secretary is disastrous for public health,” Gostin said. “Having a person sceptical of science and evidence at HHS will make America unhealthy.”

Public health victories at risk

Public health victories like vaccines and drinking water fluoridation have led to dramatic increases in life expectancy. The World Health Organization estimates vaccines save five million lives annually, with global immunization efforts having saved at least 154 million lives over the past 50 years.

Yet Kennedy has repeatedly challenged these achievements by questioning vaccine safety and stating that fluoride is linked to “neurodevelopmental disorders.”

The real-world impact of vaccine scepticism is already visible in the US, with the CDC reporting vaccination rates for children dropping for all available vaccines last year and vaccine exemptions for religious reasons rising across the past decade.

“Religion doesn’t change that fast,” said Dr Michael Mendoza, a former county Public Health Commissioner in New York State. “This is about ideology and misinformation – and we’re seeing a direct impact in the number of kids unvaccinated.”

“We’re at risk of widespread distrust in evidence-based treatments and vaccines,” Mendoza added, noting how health misinformation has directly influenced the increase in risky medical decisions. “Our elected and appointed officials have an obligation to promote experts and guidelines that are grounded in established scientific evidence.”

Within the federal workforce, many remain optimistic that little will change. Agencies like the Biomedical Advanced Research and Development Authority (BARDA), which funded the development of COVID-19 vaccines, traditionally receive bipartisan support, resulting in little change across administrations.

An HHS employee, speaking to Health Policy Watch on the condition of anonymity to safeguard their job security, noted that the negative perception of the new administration has yet to filter into many agencies.

Room for agreement 

Less controversial is Kennedy’s opposition to the well-documented “revolving door” between the industry and government, where officials frequently switch between regulating companies and working for them – a system he argues has led to the “corporate capture” of US health agencies. 

In a country that spends more on healthcare than any other developed nation, has one of the world’s highest obesity rates, and whose largest public health crisis – the opioid epidemic – was engineered by pharmaceutical giant Purdue Pharma, his critiques of the system have found resonance.

The concern about industry influence has merit: since 2000, every FDA commissioner has taken industry positions after leaving office. Nine out of the last ten, representing 40 years of leadership, have done the same. The pattern continued with Trump’s previous HHS secretary, Scott Gottlieb, who departed to a board seat at Pfizer in 2020.

Kennedy’s stance against pharmaceutical interests sets up a likely clash with fellow Republicans, many of whom receive significant industry funding. Several GOP lawmakers have already pledged to dismantle President Joe Biden’s signature Medicare drug price negotiation law, which allows the government to negotiate fairer prices on behalf of its senior citizens, claiming it stifles innovation.

Yet Kennedy has promised a direct confrontation with the industry, causing shares of major vaccine makers to plunge after Trump’s announcement of Kennedy’s selection.

“Together we will clean up corruption, stop the revolving door between industry and government,” Kennedy said.  

Kennedy’s promised crusade against chronic diseases and processed foods has also found broad support among public health officials – setting up yet another clash with a major industry traditionally aligned with Republican politics.

His pledge to strip ultra-processed foods from school lunches and crack down on food dyes has drawn bipartisan backing, though industry groups warn such moves could increase grocery prices Trump has vowed to reduce. 

“Senators may say, well, RFK Jr has good ideas like tackling chronic disease and regulating Big Food, but RFK Jr is not to be trusted after a career of peddling falsehoods,” Gostin said. “What we need is nutritional warnings on unhealthy foods, bans on targeting kids, and reduced salt and sugar.” 

Even some nutrition advocates who oppose Kennedy’s broader agenda acknowledge the need for stricter oversight of the food industry. The FDA has identified concerns about ultra-processed foods’ health impacts, though the agency says more research is needed.

The challenge, experts say, will be implementing evidence-based reforms while avoiding Kennedy’s tendency toward unproven theories about food safety.

Environmental hero to anti-vaccine empire

Headline published in the Defender, the news arm of Kennedy’s anti-vaccine outfit on November 7.

Kennedy began his career as a celebrated environmental lawyer, fighting corporate polluters and championing indigenous communities whose lands had been poisoned by industry. His aggressive prosecution of polluters helped restore the Hudson River to health, earning him Time magazine’s “Hero for the Planet” designation.

He maintains some of this environmental ethos, promising in his presidential campaign before bowing out to back Trump to tackle unsafe PFAS levels and microplastic contamination.

But his path took a sharp turn in 2015 when he took over the struggling World Mercury Project, rebranding it as Children’s Health Defense (CHD) in 2018.

Under Kennedy’s leadership, CHD became a global anti-vaccine juggernaut. The organization’s revenue skyrocketed from $1.1 million in 2018 to $23.5 million in 2022, with Kennedy himself earning more than $510,000 in 2022, the last year where filings are available. 

In mainstream interviews and congressional appearances, Kennedy has worked to promote his least controversial views. He has attempted to moderate his image, telling NBC News: “I’m not going to take away anybody’s vaccines, I’ve never been anti-vaccine.”

Yet the organization he led until his presidential campaign – and where he remains a lawyer – continues to fund and promote numerous anti-scientific positions.

Public tax filings show Kennedy made $550,000 in executive compensation from Children’s Health Defense in 2022, the last year where records are available.

During the pandemic, CHD’s vaccine-related posts were shared more frequently on Twitter than content from CNN, Fox News, NPR and the CDC combined – occasionally eclipsing the readership of the New York Times and Washington Post. The Center for Countering Digital Hate named Kennedy one of the “Disinformation Dozen,” identifying him and CHD as among the top spreaders of vaccine misinformation online.

CHD also played a role in coordinating international protests for anti-vaccine movements around the world – with deadly consequences. In 2019, Kennedy’s organization flooded American Samoa with vaccine misinformation and lobbied the government against the use of the MMR vaccine, resulting in a devastating measles outbreak. 

This week, CHD’s news arm, The Defender, published claims that COVID-19 vaccines pose a “112,000% greater risk of brain clots and strokes than flu shots” – research based on misuse of VAERS, a federal database that records unverified reports of adverse events. The study’s authors include supplement company affiliates and anti-vaccine activists who openly coordinate with Kennedy’s organization. 

One author chairs a Texas-based organization that tagged Kennedy in a Twitter post on Tuesday calling for the “immediate withdrawal of all COVID-19 vaccines from the market” and the “repeal of the 1986” national childhood vaccination act. 

In his 2021 book, which sold over a million copies and sat on the New York TImes bestseller list for 17 weeks, Kennedy expands on the ethos behind CDH, calling Anthony Fauci, who led the US response to the COVID-19 pandemic, “the powerful technocrat who helped orchestrate and execute 2020’s historic coup d’état against Western democracy,” claiming his “remedies” – including Covid vaccines – were “often more lethal than the diseases they pretend to treat.”

The book also champions Alan Duesberg, praising as “elegant” and “compelling” the discredited scientist’s claims that AIDS is not caused by HIV. Such theories had deadly consequences: 330,000 people died prematurely after being denied life-saving HIV treatment when South Africa’s government embraced view championed by Duesberg in the early 2000s, according to Harvard researchers.

Path to Senate confirmation

Kennedy’s path to confirmation runs through a Republican-led Senate, where he needs a simple majority of 51 votes. While some Republicans have expressed cautious support, experts point to Trump’s other nominees as the President-elect’s “tests” for Senate loyalty, suggesting the incoming president may bypass the traditional confirmation process entirely.

“Any Republican Senator seeking the coveted LEADERSHIP position in the United States Senate must agree to Recess Appointments (in the Senate!), without which we will not be able to get people confirmed in a timely manner,” Trump posted on Sunday. “We need positions filled IMMEDIATELY!”

If the Republican-majority Senate agrees to recess appointments – where the President appoints officials when Congress is not in session – Trump’s cabinet picks could stay until the end of 2026.

Kennedy joins other iconoclastic nominees. Trump tapped former Democratic Representative Tulsi Gabbard for Director of National Security, noted for her opposition to US support for Ukraine and promoting debunked Russian claims about US-funded biolabs there. He also named Florida Representative Matt Gaetz, who had been facing a congressional ethics investigation over allegations of sex trafficking a minor, as Attorney General.

Image Credits: Gage Skidmore.

Young Indonesians appeal for an end to TB at the Union’s World Lung Health conference in Bali.

In a breakthrough for patients with multi-drug-resistant (MDR) tuberculosis (TB), researchers shared positive trial results for a shorter, tailored alternative at the World Conference on Lung Health in Bali, Indonesia. 

The insights came from the endTB-Q trial aimed at finding a simpler, less toxic, shorter regimen for fluoroquinolone-resistant MDR-TB. Fluoroquinolone is a common class of medicine used to treat MDR TB, and if patients become resistant, they are considered to be bordering on extensively drug-resistant (XDR) TB, which is extremely hard to treat and can take 18 months.

The endTB-Q clinical trial enrolled 323 patients from India, Kazakhstan, Lesotho, Pakistan, Peru, and Vietnam to try to find alternatives to the current longer treatment regimen recommended by the World Health Organization (WHO). 

Lorenzo Guglielmetti, Médecins Sans Frontières (MSF) Director for the endTB project
Lorenzo Guglielmetti, Médecins Sans Frontières (MSF) Director for the endTB project

“Our trial innovated in several important ways. Since we know that treatment for TB is not ‘one size fits all’, we tested a strategy that tailored treatment duration to disease severity and treatment response based on simple criteria,” said Lorenzo Guglielmetti, Médecins Sans Frontières (MSF) Director for the endTB project and co-principal investigator of the trial.  

Researchers tried a combination of four TB drugs used to treat drug-resistant forms of TB –  bedaquiline, clofazimine, delamanid and linezolid (BCDL). 

These drugs were given for six months and extended to nine months in case of delayed treatment response. Around 87% of patients were cured after the treatment in comparison to  89% of patients in the control arm of the trial that received the current WHO regime.

But those 87% who did get better had less severe TB, according to the researchers. But for people with severe TB disease, BCDL for nine months was insufficient as they were at risk of TB returning and the longer regimen is still the best option.

“Our conclusions are that this regimen, BCDL, given for six to nine months, is an excellent approach for those who don’t have severe disease at baseline.  In this group, the success rate is almost 95% and it has a big advantage compared to the historical conventional treatment because it’s much shorter and less toxic,” said Guglielmetti.

Researchers shared several breakthrough insights on tuberculosis care at the World Conference on Lung Health.

Bedaquiline use in children found safe

Researchers also shared updates from a separate trial that looked into whether children can take bedaquiline, which is used to treat drug-resistant TB. The trial found the drug to have a high degree of safety and tolerance for use in children. 

New data from a different trial funded by the US-research agency National Institute of Health (NIH) called IMPAACT that included experts from Stellenbosch University in South Africa found bedaquiline safe for use in the treatment of infants, children and adolescents with drug-resistant TB. 

This is a crucial finding as it will allow further optimising the use of bedaquiline in children with drug-resistant TB – an under-served population.

“The P1108 trial [bedaquiline] has paved the way for access, finally, to effective, shorter and safer treatment for children with drug-resistant TB. For too long children with TB have been left behind,” said researcher Simon Schaaf. 

He said that children form nearly 12% of all TB cases or 1.3 million cases every year globally but despite bedaquiline being authorized for use since 2012, there wasn’t any trial for its use in children.

Nearly 3,900 stakeholders including industry representatives, patient groups, and doctors from around 150 countries attended the conference.

The week-long conference also saw the release of results from other TB trials in countries across Southeast Asia. 

In Indonesia, researchers found that using mobile chest X-ray screening proved to be a useful tool to find active TB cases in the community. This is especially helpful in cases where people do not show classic symptoms of TB like coughing.

In Vietnam, researchers stressed the importance of active case finding in ethnic minorities and remote communities to ensure access to treatment. They also used mobile X-ray machines.  

In the Philippines, person-centred active case finding for TB was found to break down barriers to healthcare access for vulnerable populations. The screening was done as a part of a poverty alleviation programme which empowered community members to participate and take a leading role. Trust in community leaders aided the screening of TB. 

Researchers also shared results from a study that highlighted the need to optimize tests to check whether a patient was susceptible to a particular drug or not, and to expand access to new TB compounds for people with life-threatening TB.

“Antimicrobial resistance is among the greatest global health threats we face today. For people at-risk of TB, this threat is multiplied,” said Dr Cassandra Kelly-Cirino, Executive Director of The International Union Against Tuberculosis and Lung Disease (The Union), which convened the conference.

“The new research presented at the Union Conference this week represents an invaluable step in managing this challenge and in offering hope to patients of all ages living with extensively drug-resistant TB.”

Image Credits: The Union, The Union.

Smog engulfs Lahore, Pakistan, on Thursday as air pollution levels hit record highs. Some pollutants reached nearly 100 times the World Health Organization’s recommended level, according to IQAir.

BAKU, Azerbaijan — Global and Indian experts at COP29 produced new evidence Thursday calling for clean air standards to become part of nations’ climate commitments, as cities across South Asia’s heavily polluted air corridor battled record-breaking smog.

In Delhi, authorities closed schools up to grade 5 and halted construction as pollution levels soared to almost twenty times the WHO’s safe daily limit. The crisis came just days after Lahore, Pakistan’s second-largest city just 25 kilometres from the Indian border, saw its highest-ever levels of air pollution. 

Under the clear skies of Azerbaijan’s capital, experts from the World Bank, WHO, and Indian health ministry were unanimous that air quality improvement should be included in the new Nationally Determined Contributions (NDCs), the self-determined climate targets nations set under the Paris Agreement. 

“Air quality targets and standards can be a perfect indicator of success if we are successful in targeting the causes of climate change,” Dr Maria Neira, WHO’s health and climate lead, told Health Policy Watch. “If we could select an indicator of how successful we are in achieving negotiations on climate change mitigation, I think we should use the levels of air quality that people around the world are breathing.”

Health experts hope their evidence linking air pollution and climate change will strengthen calls for action at COP29.

Supporting this call for action is a new report released by the Clean Air Fund that shows how tropospheric ozone – a little-discussed ‘super pollutant’ – is linked to 500,000 premature deaths and an estimated $500 billion in economic costs annually. Air pollution from all sources contributes to more than eight million premature deaths each year, with economic costs exceeding $8 trillion, the report found.

The findings aim to support the push for including air quality standards in the third generation of NDCs – binding climate commitments due before COP30 next year under the Paris Agreement. Only a small fraction of countries currently include air pollution safety in their climate plans despite the health threat to millions worldwide.

Clean Air Fund’s founder and CEO, Jane Burston, said tackling super pollutants provides “huge opportunities” for improving climate, health, economic development, and equity.

“We know that developing countries are some of the few that have included things like black carbon in their nationally determined contributions, and that’s because a lot of these deaths and this exposure is happening in countries least able to afford action on it,” she added.

Super-bad for children

Protest by ‘Warrior Moms’, a group for clean air, in Delhi outside India’s health ministry, as air pollution turned ‘severe’ on 14th November, which is celebrated as Children’s Day in the country.

Tropospheric ozone and its super-pollutant siblings – including methane, black carbon, nitrous oxide and fluorinated gases – are collectively responsible for nearly half of global warming to date.

Unlike other pollutants, tropospheric ozone isn’t directly emitted but forms when sunlight interacts with pollutants from aviation, shipping, agriculture and other sectors. Its health impacts can be severe, from reduced lung function to complications in type 2 diabetes and cardiovascular disease. For children, this pollution poses an especially severe threat.

“Young children have smaller lungs,” Dr Soumya Swaminathan, an advisor to the Indian health ministry and former chief scientist at the WHO, explained. “They breathe much faster than adults, and they are shorter, so they’re closer to the ground, where there are more pollutants, and get more respiratory infections.”

Dr Valerie Hickey, who leads the World Bank’s environment department, also placed children at the centre of her argument.

“Your kid got up coughing so bad they couldn’t go to school does not lead on CNN,” she said. “Though if there are huge floods in Valencia, it does. Both are terrible, but [air pollution] is a public health emergency.”

Like climate change itself, air pollution’s threat isn’t only visible in extreme events such as Delhi’s current crisis, where PM2.5 levels have reached almost 300 micrograms per cubic metre.

“Every unit you go above five, you actually have a health impact,” explained Swaminathan, who co-chairs Our Common Air. “Even at 20, 30, 40 you start getting effects on the heart, respiratory system, and brain. So we need to take action to keep it as low as possible.”

“We have to be pragmatic and set interim targets and do a stepwise plan to reduce it,” she added. “That’s what the NDCs are all about.”

‘Smog diplomacy’

Delhi and Lahore, just 400 kilometres apart, face the world’s highest air pollution levels.

Half of the ten most polluted places in the world today are in four countries of South Asia – Pakistan, India, Nepal and Bangladesh. Health experts often say that air pollution knows no borders, an adage now forcing cooperation between long-standing rivals in what’s come to be known as “smog diplomacy.”

India and Pakistan, nations that have fought multiple wars since independence, are finding themselves pushed toward dialogue over their shared air crisis. This week, as their major cities Delhi and Lahore traded places as the world’s most polluted, officials in Punjab, Pakistan’s most populous province, drafted a letter to India seeking talks on air pollution. 

“This is an area of the world where there isn’t always great experience with international diplomacy,” Hickey said. “Countries don’t always like each other, but they’re actually seeing that smog diplomacy is something that can bring them to the table.” 

The outreach comes as hundreds of millions in both countries face severe health risks borne from common problems plaguing both nations: farmers burning agricultural waste, coal-fired power plants, heavy traffic, construction and windless days trapping emissions.

The World Bank has launched a “multi-hundred billion dollar” to address this cross-border crisis, targeting the vast northern plains of South Asia, known as the Indo-Gangetic Plains, Hickey told Health Policy Watch.

The Bank has already committed to several regional projects in India, including a $350 million clean air management initiative plus $5 million grant for Uttar Pradesh, reportedly approved by the state cabinet and a pending $300 million loan plus $5 million grant for Haryana.

Similar programs are planned for Nepal, Pakistan and Bangladesh to address pollution that readily crosses borders due to the region’s geography and wind patterns.

“We need climate diplomacy, as a regional and global issue,” Raja Jahangir Anwar, Punjab’s Secretary for Environment and Climate Change, told CNN. “We are suffering in Lahore due to the eastern wind corridor coming from India. We are not blaming anyone, it’s a natural phenomenon.”

Image Credits: https://x.com/ThePeerAli/status/1856985454072963085/photo/1.

Thail lab technicians train in surveillance of antimicrobial resistance (AMR) in food-producing animals in Southeast Asia – an driver of AMR that was neglected in the recent UN High Level Meeting declaration.

With plans underway for a new “Independent Panel” on Antimicrobial Resistance, endorsed at September’s UN High-Level AMR Meeting, the new body must become a strong scientific authority. It should have the power to “challenge” the agencies that create it and address both human and animal health factors driving drug-resistant pathogens.

That was a key message from AMR experts in the lead up to the Fourth Ministerial Meeting on Antimicrobial Resistance, which begins Friday in Jeddah, Saudi Arabia. 

The Independent Panel “needs to be an inclusive process… listening to scientists… civil society, to industry and other actors. But you also need to make sure that that panel, even though hosted by a Quadripartite, can actually challenge the Quadripartite,” declared John Arne Røttingen, CEO of the UK-based Wellcome Trust, of the panel’s central importance to providing evidence on future AMR policies.

The ‘Quadripartite’ includes the World Health Organization, as well as the global environment, food and animal health agencies, which are now formally collaborating to confront the AMR threat.

John-Arne Røttingen, CEO of Wellcome Trust.

Røttingen was among the more than two dozen experts convened for two high-level AMR sessions at Berlin’s World Health Summit in mid-October to discuss next steps for the battle against drug resistant pathogens in the lead-up to the Jeddah meeting.

“Declarations are long. It’s hard to identify the real material commitments that have been made,”  Røttingen said at a panel discussion on Milestones and Challenges in Tackling AMR, hosted by the German Ministry of Health.

“So it’s great that we come to Jeddah for the ministerial meeting,” he said. “That should be a start of both countries’ [and development agencies]  coming together as well as the multi stakeholder partnership platform coming together across sectors to make sure that we are keeping our commitments.”

On the research front, meanwhile, new “pull incentives” recently developed in the United Kingdom, Italy and Canada to foster a sustainable market for next generation antibiotics are welcome, but they are not enough, industry experts asserted. Many more nations need to adopt supply-side incentives to ensure that badly-needed new drug candidates actually come to market.

Jeddah should be the start of making good on the UN’s AMR Declaration

FAO, UNEP, WHO and WOAH heads at September’s UN High Level Meeting that approved a set of new commitments for action on drug resistant pathogens.

The health ministers’ confab in Saudi Arabia (15-16 November) is supposed to lay out next steps for delivering on promises made in the Declaration on Antimicrobial Resistance approved at the UN High Level  Meeting, 26 September in New York City.  

September’s declaration was a major milestone in the battle to bring a long-ignored AMR epidemic to the forefront of global health policy. AMR is associated, directly or indirectly, a “silent, slow-motion pandemic” that could kill some 39 million people by 2050.

The mandate to create an “independent panel for evidence for action against antimicrobial resistance in 2025” is embedded in a 15-page text, with 106 clauses. But it is widely perceived as a key next move to maintain strategic momentum on AMR threats. 

The science panel should “facilitate the generation and use of multisectoral, scientific evidence to support Member States in efforts to tackle antimicrobial resistance, making use of existing resources and avoiding duplication of on-going efforts, after an open and transparent consultation with all Member States on its composition, mandate, scope, and deliverables,” the AMR  declaration stated.  

Final HLM declaration omitted target for reducing animal antibiotic consumption 

Asian meat-packing house.

The science panel is supposed to be created and administered by the Quadripartite of agencies whose role in managing the AMR crisis was also formalized by the declaration. Along with WHO, the four-member body includes the UN Food and Agriculture Organization (FAO), the UN Environment Programme (UNEP), and the World Animal Health Organization (WOAH), a non-UN member state body.

And that makes the panel’s mandate and composition a sensitive point, in light of the political pressures from big food and other interests that want to play down their role in fostering AMR risks, which some researchers say is the leading driver. 

Identified AMR hotspots often align with high volumes of antibiotics sales and use in livestock.

Pressures from agri-businesses and meat producing nations  already led to the deletion of a target for reducing animal antibiotic use by 30% by 2030 from the final HLM declaration. Now, the question is whether scientists can come together to articulate the evidence and agree on science-based policy recommendations.

“Even though the declaration was positive, it also didn’t achieve agreement on things that I, from my professional background, …would say should have been agreed,” Røttingen observed. “And that speaks to the interests and the trade offs between different sectors… it speaks to agri-food businesses versus human health, and that’s why we believe a science panel is important.”

He said, “We have the target of inverting AMR-related mortality [by 10% by 2030], but we need even more targets and more ambitious targets, so we have a lot to do,” he said.  

“In the climate sector, we have the IPCC (Intergovernmental Panel on Climate Change),” Røttingen continued. “We know how … contested the climate space is, but still, we have a collective international evidence base… We need authoritative evidence with scientists working in the human sector and the animal sector that can come together to actually give us that evidence base and give guidance. “

For animal health, as well, the ultimate aim is to curb abuse not essential use 

Arshnee Moodley, CGIAR-Kenya

Worldwide, the overuse of such antibiotics in livestock production is widely regarded among experts as a leading, if not the leading, driver of pathogen resistance.

But ultimately, the aim of new measures should be win-wins that ensure better access to vaccines and other measures to pre-empt antibiotic use and ensure animal health, panelists at the sessions also underlined.

 “You need to be able to communicate with the people who can change that [AMR trends],” said Dr. Arshnee Moodley, a Kenya-based lead of CGIAR, which works with farmers on animal health. “And for me, it’s the smallholder famer outside of Nairobi.  I need to be able to tell him or her why they shouldn’t use antibiotics,” she said.

“And that’s really critical because livestock is also part of the solution; it’s vital food for vulnerable groups,” she continued.

“I worked every summer in my grandfather’s farm with three milk houses, from the age of 13. So I know about animal health and the need for small farmers, even in high income countries, to keep their herds healthy,” Røttingen countered.  

“When I’m concerned about the agricultural sector, it’s not really about the misuse of antibiotics among small scale farmers … it is about big food on several continents and making sure that they are … transparent and they are willing to engage in proper animal welfare, because that’s the starting point for ensuring animal health.

Too often, measures related to vaccines and hygiene are bypassed, “by using antibiotics to treat herds that aren’t necessarily requisite,” he explained.

Worst of all, is the use of antimicrobials or antibiotics “as growth promotion that has nothing to do with animal health. It’s not healthy for those who eat those animals, and it’s not healthy for the animals.

“So … animal health is an important part, but I think the hardest question lies with the big food companies.”

For human health – more prevention and better regulation are essential too

Malawi’s Minister of Health Khumbize Kandodo Chiponda with Tamas Koncz, Pfizer Germany

Much as with animals, infection prevention, appropriate access to drugs and better regulation need to be the operative goals for humans as well, panelists at a second high-level session on AMR agreed.  

That includes clean water, sanitation and hygiene that many communities and health facilities still lack, as well as stronger laboratory networks, and quality control of antimicrobials in settings were fake and substandard formulas often circulate.  

“Unfortunately for countries like us, we face challenges, because in terms of manufacturing…  we have to get them [products] from outside. So in terms of the quality…. you cannot be 100% sure that what you’re getting really is the very, very good quality,” said Khumbize Kandodo Chiponda Minister of Health, Malawi, speaking at the panel hosted by the global non-profit antibiotic accelerator CARB-X and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

Changing community behaviours and patterns can be a major lift, in light of the ease with which people can get antibiotics through more informal channels as well as the expense people might face in seeing a healthcare professional – who will in turn face challenges determining if antibiotics are needed or not – without adequate diagnostics equipment.  

Access to antibiotics is improving – but Africa is also becoming an AMR hotspot

Buying antibiotics in India. Prescriptions are required but the rule is not always enforced.

“Access to antibiotics [in LMICs] is improving and that is a good thing,” said Tamas Koncz, a vice-president of Pfizer’s operations in Germany. He pointed to data citing a 114% increase in antibiotic use in low- and middle-income countries between 2000-2015.  Pfizer’s 2022 Accord for a Healthier World,  which committed to providing all of its patented medicines and vaccines to 45 lower-income countries on a not-for-profit basis, has been one enabler of better access to common antimicrobials, he said. At the same time, weak enforcement of prescription drug rules, as well as a lack of health provider knowledge about which drugs to prescribe, are drivers of drug resistance.   

“If physicians are not using [the drugs] appropriately, then it’s going to lead to problems. So we need to fix the challenge of access. But I think what is even more important is the overall approach.”

Africa, where sales of antibiotics by unlicensed vendors is often widespread, is also becoming a major AMR hotspot, he pointed out – highlighting the challenges of balancing access with judicious use. 

All-age rate of deaths attributable to/associated with antibiotic resistance, 2019. (Lancet, 2022)

The landmark 2022 Lancet study that found 1.27 million deaths globally in  2019 were directly attributable to drug-resistant bacterial infections, including 860,000 in Africa. That same year, Africa saw 640,000 deaths from HIV.  

“We know from the recent communication from the African CDC and others, that it’s becoming probably the one of the biggest, if not the biggest, healthcare burden, superseding now HIV AIDs, maybe even malaria and tuberculosis,” said Koncz.  

‘Pull’ incentives 

Florence Séjourné, Aurobac and Kevin Outterson, CARB-X.

On the supply side of the equation, meanwhile, “more pull incentives” that can incentivize pharma developers of newer, pathogen-resistant antibiotics is a long-neglected topic now finally rising to the top of health ministers’ agendas.  

The challenge lies in the fact that new antibiotics capable of beating drug-resistant infections also need to used sparingly – to ensure that they, too, don’t fail prey to AMR. But that means companies that develop the drugs can’t count on revenues from blockbuster sales to pay back years of investment in clinical trials. 

“AMR innovation is in a broken business model right now, needing incentives.” said Florence Séjourné. She is the CEO of the Aurobac Therapeutics, a joint AMR R&D venture created by two leading European pharma firms as well as the founder of the BEAM Alliance association of AMR-focused biotechs.  

Products risk death in the pipeline 

While there are now 20 “highly innovative” antibiotics in the early stages of development globally, the number will have dwindled by 75% within eight years if the business model doesn’t change, warned Dr Kevin Outterson, head of CARB-X.  “Within four years, we’ll have less than 10 in clinical development globally. And four more years after that, we’ll have less than five.” 

The of human capital” he added as large companies shut down programmes, and research is concentrated in underfinanced biotech startups. 

“There is absolutely no interest in private investors in the antibacterial field, which is complex,” added Séjourné. Of the startups, 60% of the BEAM Alliance members have less than a year of cash to fund their activities; 40% are firms of less than 9 employees.  

“The world is relying on micro companies, companies with less than 10 employees…That’s a very fragile base,” for developing urgently needed new drugs, Outterson added. 

On the cusp of a solution? 

Bacterial culture prepared for testing new antibiotic candidates.

But, there are also some glimmers of hope on the horizon. 

The first was the launch of the United Kingdom’s new “subscription model” in May for antimicrobial drugs that need to be held in ‘reserve’ for drug resistant pathogens. This aims to guarantee innovators a return on new drugs, regardless of the quantities used, that can guarantee a market incentive for new drugs, even if they are carefully rationed. 

Séjourné praised the UK decision as “something to highlight has a good example for others to follow” – although she warned that until a larger number of countries get on board with such changes, “the broken business model will remain.” 

More recently, at the 10 October meeting of G7 health and finance ministers in Ancona, Italy’s  Minister of Health, Orazio Schillaci announced a series of new “pull incentives” aimed at stimulating R&D and ensuring biotech firms a payback on their investment. Canada is also piloting an incentive programme, while other European Union members, as well as Japan, are considering similar moves. 

In light of those new developments, CARB-X’s Outterson sounds a note of cautious optimism. 

“At the G7 meeting, I made the economic case for a small, reasonable investment and push and mostly pull incentives, together, yields an amazing return on investment, both on the health side as well as the economic side,” Outterson said. “It was a rare opportunity to be able to speak not just to the health people, but also the finance people,” he said, noting that the issues raised at the meeting appeared to resonate with both sectors. 

“And so we have a problem, and we know that it’s desperate, and companies are filled with innovation, but not enough capital to move things forward. But we really are on the cusp of the solution as well.”

IFPMA Director David Reddy

“The UN meeting finished only a few weeks ago,” said IFPMA director David Reddy. “We’re moving towards the meeting in Saudi Arabia, which is the fourth AMR high level event.

“I think one thing that is really important is that we are getting a common understanding of where we need to go, and what the challenges are,” he added. “We do need to make progress on the business model. The UK, Japan have already made good moves towards pull incentives, and a pilot has been put in place by Canada. There are a lot of remaining challenges, but I think the key message coming out of this is there is a real thirst to maintain momentum as we head into the meeting in Saudi Arabia.” 

But “it’s not just about financing,” he added, “it’s also about people and competencies.” 

“Access but having a really firm understanding of community needs on the ground is essential, because without that, we won’t make progress in the fight against AMR and in bringing antibiotics to those who need them.” 

Image Credits: USAID Asia/Flickr, USAID Asia , Health Policy Watch , Van Boeckel, Pires et al, 2019, WHO, The Lancet, 2022, AMR Industry Alliance.

WHO senior technical advisor on measles Dr Natasha Crowcroft

Inadequate immunisation is driving the global surge in measles cases, with an estimated 10.3 million cases in 2023 – a jump of 20% since 2022.

This is according to new estimates from the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC). 

A total of 57 countries experienced large outbreaks in 2023, in comparison to 36 countries in the previous year. 

Europe’s measles cases increased by 200% – from 100,000 cases to just over 300,000 cases.

An estimated 107,500 people, mostly children under the age of five, died of measles in 2023, an 8% decrease from the previous year.

“This slight reduction in deaths was mainly because the surge in cases occurred in countries and regions where children with measles are less likely to die due to better nutritional status and access to health services,” according to Dr Christine Dubray, CDC Measles Elimination Team Lead

But Dr Natasha Crowcroft, WHO senior technical advisor on measles, said it is “very hard with the level of data we have” to be able to say why this had happened.

“Vaccine hesitancy plays a part in all regions of the world, so we know that’s in there somewhere,” said Crowcroft.

However, she said that deaths were in vulnerable communities with high rates of malnutrition, poor health services and often also conflict. 

“In the African region, the number of deaths increased by 37%,” she said. Africa had  4.5 million cases in 2023, and 71% of global deaths.

At least 95% of children need to be vaccinated with two doses of the measles vaccine to prevent outbreaks of one of the world’s most contagious viruses.

CDC and WHO are founding members of the Measles & Rubella Partnership (M&RP), a global initiative to stop measles and rubella.

Sudan
UN chief António Guterres has called the situation in Sudan “a nightmare of violence”.

The death toll in Sudan’s civil war is likely far higher than reported as violence, hunger and disease devastate Africa’s third-largest nation, a new study shows.

More than 61,000 people have died in Khartoum state, the capital region where fighting began 14 months ago, according to research from the London School of Hygiene & Tropical Medicine. Among the dead, over 26,000 were killed by violence – surpassing the United Nations’ nationwide count of 20,178 violent deaths reported by crisis monitor ACLED.

The death count in Khartoum, just one of Sudan’s 18 states, suggests official figures severely undercount the number of lives lost in what the UN and aid groups call the world’s worst humanitarian crisis.

Researchers found starvation and disease are the leading causes of death across most of the country, while violence claims the most lives in Kordofan and Darfur, where ethnically targeted attacks and intense fighting continue.

“Our findings reveal the severe and largely invisible impact of the war on Sudanese lives, especially preventable disease and starvation,” said Dr Maysoon Dahab, lead author of the report and infectious disease epidemiologist at LSHTM. “The overwhelming level of killings in Kordofan and Darfur indicate wars within a war.”

The war has transformed Sudan from Africa’s largest agricultural producer and regional breadbasket into a nation where 750,000 civilians now face famine conditions, driving 11 million people from their homes in what the UN calls the world’s largest displacement crisis. Half of Sudan’s population – 24.8 million people – now depends on aid to survive.

“Sudan is trapped in a nightmare,” Rosemary DiCarlo, UN Under-Secretary-General for Political Affairs, told the Security Council on Wednesday. “The people of Sudan need an immediate ceasefire.”

Healthcare collapse fuels rising death toll

pollution
Khartoum, Sudan.

The war’s deadliest long-term impact may be its destruction of Sudan’s health and sanitation services. Disease and starvation now account for about half of all deaths in Khartoum amid an acute health crisis sweeping the country, the study found.

Eight in ten hospitals in conflict zones have shut down, leading to a sharp rise in deaths from infectious, non-communicable, maternal, neonatal and nutritional diseases that researchers called “significant, unrecorded and largely preventable.”

An unusually heavy rainy season has fueled a severe cholera outbreak, with contaminated water driving more than 28,000 cases across 11 states, and a surge in dengue fever that has resulted in 12 confirmed deaths since July, according to the UN Office for the Coordination of Humanitarian Affairs (OCHA). 

Disease counts, like death tolls, represent only a fraction of the crisis, OCHA said. Millions remain cut off from care as outbreaks spread undetected beyond the reach of Sudan’s devastated health surveillance systems.

Half of Sudan’s population needs humanitarian assistance, yet aid remains out of reach for most. Aid groups “remain unable to reach the vast majority of people in conflict hotspots,” UN emergency coordinator Ramesh Rajasingham told the Security Council on Wednesday.

“Some areas are completely cut off,” Rajasingham said. “We urgently need the parties to ensure the safe, rapid, unimpeded movement of both relief supplies and humanitarian personnel via all available routes.”

‘Invisible’ deaths go uncounted

Aid arrives in Sudan as over half the country faces dire humanitarian needs.

Sudan’s ability to count its dead has long been fragile, with no national census conducted in over a decade. Even Khartoum, the capital region, captured just 3-6% of COVID-19 deaths during the pandemic, researchers estimate.

The war has shattered this already weak system. Morgues and hospitals that typically record deaths are now inaccessible or offline, while military factions have weaponized telecommunications, implementing blackouts that further obstruct data collection.

More than 90% of deaths documented in the new study went unrecorded in official tallies. Sudan’s Health Ministry claims just 5,565 war-related deaths have occurred to date.

Dahab said while the team could not estimate mortality levels beyond Khartoum or determine total war-linked deaths nationwide, their assessment offers the first systematic mapping of death patterns during the conflict. 

“The number might even be more,” Abdulazim Awadalla, program manager for the Sudanese American Physicians Association, told Reuters. “Simple diseases are killing people.”

Foreign powers ‘enabling the slaughter’

As disease, hunger and violence claim more lives, evidence mounts that foreign powers are intensifying and prolonging Sudan’s humanitarian catastrophe.

French weapons have been identified in the hands of the Rapid Support Forces (RSF), Amnesty International revealed Thursday, adding to a complex web of international involvement in the conflict.

“Our research shows that weaponry designed and manufactured in France is in active use on the battlefield in Sudan,” said Agnès Callamard, Amnesty International’s Secretary General. The weapons reached RSF through France’s defence partnership with the United Arab Emirates, which has emerged as a key backer of the paramilitary group.

“To put it bluntly, certain purported allies of the parties are enabling the slaughter in Sudan,” DiCarlo, the UN Under-Secretary-General for Political Affairs, told the Security Council. “Both warring parties bear responsibility for this violence.” 

A UN fact-finding mission released in September found both the RSF and government forces have committed potential war crimes and crimes against humanity. The RSF and allied militias face additional accusations of genocide and using mass rape as a weapon of war, particularly in Darfur.

Despite a UN arms embargo, weapons continue flowing to both sides through neighbouring countries, several of which, including Libya, Chad and the Central African Republic, are major arms trafficking hubs, UN experts say. 

While Egypt and Saudi Arabia back government forces, the UAE, Libya and Russian-linked Wagner Group support the RSF. The UAE has invested over $6 billion in Sudan since 2018, viewing the resource-rich nation as key to expanding its regional influence.

“All countries must immediately cease direct and indirect supplies of arms and ammunition to the warring parties,” Callamard said. “They must respect and enforce the UN Security Council’s arms embargo regime on Darfur before even more civilian lives are lost.”

Image Credits: @UNHCR, State of Air Quality and Health Impacts in Africa .

Testing for mpox will soon be done using tests made in Morocco.

African countries will soon use a PCR test for mpox developed by Moroccan company Moldiag that is cheaper than the Gene Xpert tests currently being used, according to the Africa Centres for Disease Control and Infection (Africa CDC).

“This test was approved after a number of tests were done in the [Democratic Republic of Congo] to ensure that it is sensitive to clade 1b and other clades in Africa,” Africa CDC Director General Jean Kaseya told a media briefing on Thursday.

“The cost is $6 per test, very comparable with [test] kits that are coming from Korea and China,” said Dr Yenew Kebede Tebeje, Africa CDC’s head of laboratory systems.

“But Morocco has also offered that if we can buy in large quantities, they can bring down the cost to $5 per test. As compared to Gene Xperts, this is very, very cheap, even twice as cheap.” 

Dr Yenew Kebede Tebeje, Africa CDC’s head of laboratory systems.

Africa CDC’s Diagnostic Advisory Committee (DAC) recommended the Moldiag test after it has “reviewed the evidence about this test based on set criteria, including independent evaluation data from the  National Institute for Biomedical Research in the DRC and concluded that it fulfilled all the major criteria”, according to a statement from Africa CDC.

Moldiag CEO Nawal Chraibi stated that her company is “dedicated to supporting Africa’s health resilience through the development of locally manufactured diagnostic tools. 

“We believe that strengthening local production is key to empowering the continent in its epidemic preparedness and response, allowing us to respond rapidly and effectively to public health challenges,” added Chraibi.

With 2,836 new cases and 34 deaths confirmed in the past week, Kaseya warned that mpox “is not under control in Africa”. 

The Africa CDC once again highlighted its concern about Uganda’s mpox outbreak, with 184 new cases in the past week.

While mpox vaccination campaigns in the DRC and Rwanda have met or surpassed targets, Nigeria has postponed the start of its vaccinations until 18 November.

Meanwhile, the LC16 vaccines from Japanese company KM Biologics have not yet arrived as agreement has yet to be reached on who assumes liability for adverse events, said Kaseya.

“As you know, every time that a new vaccine is introduced in the country, somebody has to sign for the insurance to be able to take care of possible side-effects,” he added. “I think that’s the issue that is now being discussed with the Japanese government to find someone that will take care of the liability issues. I think that is the only issue that is left.”

Unlike Bavarian Nordic’s MVA-BN mpox vaccine, the LC16 vaccine is licensed for children under the age of 12. Around 38% of those infected with mpox are children.

No new Marburg cases

Rwandan Health Minister Dr Sabin Ntsanzimana

Meanwhile, Rwanda has not had any new Marburg cases for almost two weeks, no deaths in a month and the last patients who were being treated were discharged a week ago, according to Health Minister Dr Sabin Nsanzimana.

While the country has to wait 42 days before it can declare that the outbreak has ended, Nsanzimana said the country has “made very good progress”.

Rwanda also effectively contained the outbreak and no Marburg cases have been detected outside its borders.

Nsanzimana revealed that the index case – a miner who contracted Marburg from fruit bats in a cave outside Kigali – has survived, but his wife and newborn child were killed by the deadly virus.

Rwanda, a small country the size of Haiti, has expanded its surveillance of bats to “all caves in the country”, the health minister added.

“We are now monitoring the movements of these fruit baths with different technology and a different combination of teams, from animal and human health using the One Health framework,” added Nsanzimana. “It’s an opportunity for us to expand our preparedness capabilities.”

Of the 66 people infected with Marburg, 51 have recovered – a comparatively low case fatality rate of 22.7%. There will  also be “continuous” follow-up of the survivors, said Nsanzimana.

Image Credits: Africa CDC.

A patient with diabetes has his blood pressure tested. Integration of care is important for patients’ wellbeing.

ISLAMABAD – Muhammad Waqas is an engineer at a private telecom company. He still remembers the day six years ago in 2018 when he was diagnosed with diabetes at the age of 30. It completely changed his life.

The diagnosis was particularly shocking for Waqas as neither of his parents had the disease, and he had always been physically fit and participated in all kinds of sports since his school days.

“It was September 2018 when I started feeling the need to urinate frequently and experienced weakness and fatigue. I consulted my doctor, who pricked my finger to take a blood sample and checked it with a glucometer. He was also prescribed an HBA1C test,” said Waqas.

Muhammad Waqas was shocked to get a diabetes diagnosis at the age of 30.

The next day, when the test report came, and Waqas’ diabetes was confirmed. Initially, he tried to control the disease through oral medication, but it didn’t work and eventually his doctor put him on insulin.

“I have been on insulin for the past six years, which has completely changed my life. Now, I have to constantly worry about my blood sugar levels and stay in touch with my doctor. I have to carry my insulin bag with me wherever I go,” he said.

World’s highest prevalence of diabetes

Some 33 million Pakistanis – or 26% of the adult population – are living with diabetes, according to the International Diabetes Federation (IDF) citing data from its 2021 report. 

Along with Pakistan, high diabetes prevalence (in black) is an issue in multiple Middle Eastern and North African countries, as well as in Mexico and several Asain-Pacific Island states.

Pakistan has the world’s highest adult prevalence rate. It ranks third in absolute numbers, following China and India which each have a billion people living with diabetes. More than one-third of Pakistan’s cases are undiagnosed, the fourth highest in global rankings. 

In addition, Pakistan’s population with diabetes could nearly double to 62 million by 2045, if more preventative action isn’t taken, the IDF warns. Worldwide, meanwhile, more than half a billion people are living with diabetes. 

Pakistan leads the world in per-capita diabetes prevalence amongst adults.

Trends in the country are even more disturbing in light of Pakistan’s health history, said Dr. Zafar Mirza, former director of Health Systems at the World Health Organization (WHO) in an interview with Health Policy Watch. 

In 1990, diabetes didn’t even appear among the 25 leading causes of disability-adjusted life years in Pakistan. However, in the decade between 2009 and 2019, death and disability due to diabetes increased by 87%.

Waqas adds that people in Pakistan are generally not aware of how to prevent diabetes.

‘Physical activity is like medicine’ 

Exercise is like medicine, but many Pakistan residents don’t do enough exercise.

Zubair Faisal Abbasi, advisor at the Centre for Governance and Public Accountability (CGPA) for food, nutrition, and public health programs, believes that the challenge of diabetes in the ciuntry is the challenge of failed food governance, failure of adaptation to new urban lifestyles, and patchy availability of standard treatments.

Food governance means that Pakistan has been unable to formulate and execute best-practice policies to control dietary risk factors such as free sugars and industrially produced transfatty acids at the population levels, according to Abbasi.

“[The government] has failed to create public awareness that physical activity is like a medicine, which is required for everyone in every age group. In addition, since fiscal allocations for health are low, the country is not able to provide standard treatments such as screening for the pre-diabetic, and treatments for diabetes-related ailments,” said Abbasi.

Mirza attributes the high burden of diabetes in Pakistan to co-existing environmental and genetic factors, with environmental factors as a major reason.  Sedentary lifestyles along with carb- and sugar-heavy diets are considered to be the main causes behind Pakistan’s high prevalence of diabetes, a trend he described, tongue-in-cheek, as “bittersweet”.

Mizra added that genetic factors become more significant due to repeated marriages among close relatives in Pakistan, which has increased the chances of diabetes.

 The burden

Mirza said the vast majority of people with diabetes have Type 2 diabetes associated with lifestyle, while Type 1 or insulin-dependent diabetes, affects a relatively small number of people.

Dr Zafar Mirza

In Type 1 diabetes, the pancreas no longer produces insulin, and patients diagnosed with this type are completely dependent on insulin. Meanwhile, Type 2 diabetes prevents the body from using insulin properly, which can lead to high levels of blood sugar. Type 2 leads to serious physical damage, especially to the feet, eyes, kidneys and heart.

According to official data obtained by Health Policy Watch, around 53% of deaths in the country are the result of non-communicable diseases (NCD), with diabetes being one of the major causes.

Official data said 41.4 % population (53.7% of females and 24.7% males) do not meet the physical activity standards recommended by WHO for the prevention of NCDs including diabetes.

Treatment challenges

Taskeen Arshad, 55, is a housewife who has been fighting diabetes for the last 10 years. Her mother also had the disease, and she died of it at the age of 69. Arshad pays monthly visits to the Pakistan Institute of Medical Sciences, a government-run tertiary care hospital in the federal capital, to get free medicines for diabetes.

She cannot afford to purchase diabetes medicine from a private pharmacy and is dependent on the government’s social security program for her treatment.

“Not every time I get free medicine from this government hospital. Sometimes it’s not available for three to six months. The hospital administration tells us the medicine was not procured because of shortage of funds,” said Arshad.

The non-availability of medicines from the government hospital makes her reliant on relatives to pay for the medicines at private pharmacies.

Noor Mahar, the president of Drugs Lawyers Forum, a watchdog for medicine pricing, said the availability and pricing of diabetes medicine is a serious issue: “Federal government has removed the pricing cap from the medicine which resulted in the price hike of insulin and other medicines up to 400% now.”

 He alleges that sometimes pharmaceutical manufacturers and importers create artificial shortages in the market to increase prices, which results in the suffering of those who depend on the medicines.

“The shortage is not only reported in the private market but also government hospitals usually run short of medicines,” said Mahar.

But Asim Rauf, CEO of the Drugs Regulatory Authority of Pakistan (DRAP), a federal body regulating drug prices and ensuring their availability in the country, said there is no shortage of insulin or other medicines in the country.

He said the prices of medicines in the market vary because of the depreciation of the Pakistani rupee in the international market against the US dollar.

“Whether it is the raw material or the imported medicine, the Pakistan medicine market will be affected by the fluctuation of the dollar rate,” he said.

Primary healthcare focus

Sajid Shah, spokesperson for the Ministry of National Health Services Regulation and Coordination (NHSR&C), said the ministry coordinates with provinces to provide health facilities to prevent and treat NCDs at the primary healthcare level.

The mandate of provinces is to provide free-of-cost services including glucometers, medicines, and other early-detection facilities, and treatment, and also educate people about the disease at service delivery points, he added.

“Every Tehsil Headquarters Hospital (THQ) has an NCD centre for prevention and treatment of diabetes,” said Shah.

However, healthcare officials working at PHC believe that although the government established NCD centres at THQ and District level, on the ground they still lack the facilities and are not functional according to their capacity.

A senior doctor at THQ Gujjar Khan told Health Policy Watch that his facility has an NCD center but it lacks the capacity to provide a full range of services to patients visiting for diagnoses and treatment of diabetes.

“We have glucometers but insulin and medicines for diabetic patients have not been available for the past one and a half years,” said the doctor.

He also said another important issue is the shortage of staff at the PHC level, nearly half of the strength at this level leaves the country because of attractive salary packages offered abroad which impacts the working of NCD centers.

“However all the diagnoses, treatment, and medicine are provided free of cost to the people depending on their availability,” he said.

What needs to be done?

Zubair Faisal Abbasi, advisor at the Centre for Governance and Public Accountability (CGPA)

Abbasi says that the country needs to implement primordial prevention – targeting the social and environmental conditions – as a priority, and doing this involves policy coordination.

“For example, it needs to increase taxes on sugary drinks, ultra-processed foods, and tobacco and look at its patterns of urbanization to reduce the burden of NCDs,” said Abbasi.

Mirza said the current rate of NCDs cannot be dealt with at big hospitals but requires a strong primary healthcare with trained community health workers.

Early diagnosis through mass screening and proper management are vital, as is the integration of service delivery of preventive, curative, and rehabilitative health services, he added.

“Our health system is not equipped to deal with the epidemic of diabetes. It needs sustained and coordinated whole-of-government and societal efforts and the private health sector also has to be taken into the loop,” he said.

Image Credits: WHO/A. Loke, IDF Atlas 2021, IDF Diabetes Atlas 2021 .